▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3829 by analyst upside · 2026-09-26
PLSE
Pulse Biosciences, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+4.6%
implied upside to consensus target
Current Price $51.63
Consensus Target $54.0
Bull Target $73.0
Bear Target $35.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
0
Sell
0
52-Week Low $12.56
52-Week High $58.9
YTD Return +285.6%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.17
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $12.56
52-Week High $58.9
Current Price $51.63
Bear Target $35.0
Bull Target $73.0
● Now $51.63 ● Target $54.0
TRADING DATA
Avg Volume 482K
YTD Return +285.6%
Analyst Count 6
Consensus Buy
Upside to Target +4.6%
Last Updated 2026-09-26

ANALYST SUMMARY

Pulse Biosciences, Inc. (PLSE) is currently trading at $51.63 with a Wall Street consensus price target of $54.0, implying potential upside of 4.6% over the next 12 months. 6 analysts currently cover PLSE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $73.0, while the most cautious has a target of $35.0.

PLSE operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 285.6% year-to-date and is currently trading near the upper end of its 52-week range of $12.56 – $58.9.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PLSE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG ● Initiated
Buy 2026-09-23 38% win rate (8 calls)
Freedom Capital Markets ● Initiated
Buy 2026-09-09 Building track record
Needham ● Initiated
Buy 2026-08-17 20% win rate (5 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-08-10 Building track record
Canaccord Genuity ● Initiated
Buy 2026-06-04 Building track record
Oppenheimer ● Initiated
Outperform 2025-07-07 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
57
out of 100
Coverage depth
15/30
Consensus clarity
15/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →